ATOS
Price
$0.84
Change
+$0.02 (+2.44%)
Updated
Jul 2, 04:59 PM (EDT)
Capitalization
108.13M
46 days until earnings call
PDSB
Price
$1.27
Change
+$0.05 (+4.10%)
Updated
Jul 2 closing price
Capitalization
58.05M
41 days until earnings call
Interact to see
Advertisement

ATOS vs PDSB

Header iconATOS vs PDSB Comparison
Open Charts ATOS vs PDSBBanner chart's image
Atossa Therapeutics
Price$0.84
Change+$0.02 (+2.44%)
Volume$6.32K
Capitalization108.13M
PDS Biotechnology
Price$1.27
Change+$0.05 (+4.10%)
Volume$644.67K
Capitalization58.05M
ATOS vs PDSB Comparison Chart in %
Loading...
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATOS vs. PDSB commentary
Jul 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATOS is a Hold and PDSB is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 03, 2025
Stock price -- (ATOS: $0.84 vs. PDSB: $1.27)
Brand notoriety: ATOS and PDSB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATOS: 51% vs. PDSB: 106%
Market capitalization -- ATOS: $108.13M vs. PDSB: $58.05M
ATOS [@Biotechnology] is valued at $108.13M. PDSB’s [@Biotechnology] market capitalization is $58.05M. The market cap for tickers in the [@Biotechnology] industry ranges from $306.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.33B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATOS’s FA Score shows that 1 FA rating(s) are green whilePDSB’s FA Score has 0 green FA rating(s).

  • ATOS’s FA Score: 1 green, 4 red.
  • PDSB’s FA Score: 0 green, 5 red.
According to our system of comparison, both ATOS and PDSB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATOS’s TA Score shows that 2 TA indicator(s) are bullish while PDSB’s TA Score has 5 bullish TA indicator(s).

  • ATOS’s TA Score: 2 bullish, 5 bearish.
  • PDSB’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, PDSB is a better buy in the short-term than ATOS.

Price Growth

ATOS (@Biotechnology) experienced а -2.87% price change this week, while PDSB (@Biotechnology) price change was -15.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.32%. For the same industry, the average monthly price growth was +33.16%, and the average quarterly price growth was +1.56%.

Reported Earning Dates

ATOS is expected to report earnings on Aug 18, 2025.

PDSB is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Biotechnology (+1.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATOS($108M) has a higher market cap than PDSB($58.1M). ATOS YTD gains are higher at: -11.334 vs. PDSB (-22.086). ATOS has higher annual earnings (EBITDA): -28.04M vs. PDSB (-33.08M). ATOS has more cash in the bank: 65.1M vs. PDSB (40M). ATOS has less debt than PDSB: ATOS (0) vs PDSB (19M). ATOS (0) and PDSB (0) have equivalent revenues.
ATOSPDSBATOS / PDSB
Capitalization108M58.1M186%
EBITDA-28.04M-33.08M85%
Gain YTD-11.334-22.08651%
P/E RatioN/AN/A-
Revenue00-
Total Cash65.1M40M163%
Total Debt019M-
FUNDAMENTALS RATINGS
ATOS vs PDSB: Fundamental Ratings
ATOS
PDSB
OUTLOOK RATING
1..100
2677
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
34
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
5265
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATOS's Valuation (26) in the Medical Specialties industry is in the same range as PDSB (34) in the Pharmaceuticals Major industry. This means that ATOS’s stock grew similarly to PDSB’s over the last 12 months.

ATOS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as PDSB (100) in the Pharmaceuticals Major industry. This means that ATOS’s stock grew similarly to PDSB’s over the last 12 months.

ATOS's SMR Rating (96) in the Medical Specialties industry is in the same range as PDSB (98) in the Pharmaceuticals Major industry. This means that ATOS’s stock grew similarly to PDSB’s over the last 12 months.

ATOS's Price Growth Rating (52) in the Medical Specialties industry is in the same range as PDSB (65) in the Pharmaceuticals Major industry. This means that ATOS’s stock grew similarly to PDSB’s over the last 12 months.

ATOS's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as PDSB (100) in the Pharmaceuticals Major industry. This means that ATOS’s stock grew similarly to PDSB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATOSPDSB
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 6 days ago
80%
Bullish Trend 21 days ago
86%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
N/A
Bullish Trend 1 day ago
88%
Aroon
ODDS (%)
N/A
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GRDAF0.02N/A
+4.55%
Grounded Lithium Corp
WPLCF14.410.16
+1.16%
WISE PLC
PREUF0.16N/A
N/A
Prosperity Real Estate Investment Trust
MURSF0.03N/A
N/A
Murray & Roberts Holdings Ltd.
NDGPF0.39N/A
N/A
Nine Dragons Paper Holdings Ltd.

ATOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATOS has been loosely correlated with ABOS. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ATOS jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATOS
1D Price
Change %
ATOS100%
+1.57%
ABOS - ATOS
47%
Loosely correlated
+2.25%
IMNM - ATOS
44%
Loosely correlated
+1.95%
GBIO - ATOS
44%
Loosely correlated
+5.59%
NRIX - ATOS
43%
Loosely correlated
+6.23%
KALV - ATOS
43%
Loosely correlated
+1.64%
More